Publications by authors named "Catalina Requejo"

Claim this Profile
H
HUMANISE: Human-Inspired Smart Management, towards a Healthy and Safe Industrial Collaborative Robotics.
Karmele Lopez-de-Ipina, Jon Iradi, Elsa Fernandez, Pilar M Calvo, Damien Salle, Catalina Requejo

Sensors (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation.
Sergio Vegas-Suárez, Teresa Morera-Herreras, Catalina Requejo, José Vicente Lafuente, Rosario Moratalla

Front Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of 5-HT receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats.
Sergio Vegas-Suárez, Asier Aristieta, Catalina Requejo, Harkaitz Bengoetxea, José Vicente Lafuente

Br J Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Fine Motor Skills in Essential Tremor: Combining Neuroimaging and Handwriting Biomarkers for Early Management.
Karmele Lopez-de-Ipina, Jordi Solé-Casals, José Ignacio Sánchez-Méndez, Rafael Romero-Garcia, Elsa Fernandez, Catalina Requejo

Front Hum Neurosci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson's Disease: Exploring Prodromal Biomarkers.
Catalina Requejo, Karmele López-de-Ipiña, José Ángel Ruiz-Ortega, Elsa Fernández, Pilar M Calvo

Front Neurosci· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.
Sergio Vegas-Suárez, Clarissa Anna Pisanò, Catalina Requejo, Harkaitz Bengoetxea, Jose Vicente Lafuente

Br J Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanodelivery of therapeutic agents in Parkinson's disease.
José Vicente Lafuente, Catalina Requejo, Luisa Ugedo

Prog Brain Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation.
Sara Hernando, Catalina Requejo, Enara Herran, Jose Angel Ruiz-Ortega, Teresa Morera-Herreras

Neurobiol Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease.
Jose V Lafuente, Catalina Requejo, Alejandro Carrasco, Harkaitz Bengoetxea

Int Rev Neurobiol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.
Enara Herrán, Catalina Requejo, Jose Angel Ruiz-Ortega, Asier Aristieta, Manoli Igartua

Int J Nanomedicine· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.
Enara Herrán, José Ángel Ruiz-Ortega, Asier Aristieta, Manoli Igartua, Catalina Requejo

Eur J Pharm Biopharm· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis